BioMarin Pharma (BMRN) Tops Q3 EPS by 15c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $99 at RBC Capital
October 26, 2018 7:09 AM EDTRBC Capital analyst Kennen MacKay raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $99.00 (from $98.00) while maintaining a Sector Perform rating following results.
The analyst notes strong Q3 with top/bottom line beats and tantalizing hints at pipeline updates at the upcoming Nov7 RnD Day.
... More
